Skip to main content
Caplight Logo









Excision BioTherapeutics

Excision BioTherapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://excision.bio

Last Round

Grant

Sep 29, 2022

Total Funding Raised

$76.85M

Company Overview

Excision BioTherapeutics is a biotechnology company developing CRISPR-based gene editing therapeutics to cure viral infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyCRISPRgene editingCRISPR therapeuticsviral cureHIV curein vivo therapynuclease technologybiotechnologyclinical-stage biotechgenomic medicineprecision medicineDNA excisiongenetic engineeringdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Excision BioTherapeutics Comparables

Compare Excision BioTherapeutics with similar companies based on industry and business-model similarity.

Excision BioTherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
American Gene Technologies
84%
Shanghai Bendao Gene Technology
77%
Intellia Therapeutics
75%

Excision BioTherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 29, 2022
Series AFeb 17, 2021
SeedSep 6, 2017

Excision BioTherapeutics Investors

Notable investors and investment history

Excision BioTherapeutics investors
InvestorRounds
GreatPoint VenturesSeries A
Cota CapitalSeries A
GaingelsSeries A
GreatPoint VenturesSeries A
WRVI CapitalSeries A
ARTIS VenturesSeries A, Seed
BiovergeSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 17, 2025

    Presented data at the ICE-HBV Hepatitis B Cure Symposium.

  • Sep 17, 2025

    EBT-107 program shows safety and potency for hepatitis B treatment.

Excision BioTherapeutics Filings

Explore SEC and related filing metadata, where available.

Excision BioTherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Excision BioTherapeutics's valuation, stock price, and market status.

Is Excision a public or private company?

Excision is a private company.

What is the current stock price of Excision?

Excision is a private company with no public stock price. No recent secondary market data is available.

How much is Excision worth (valuation)?

Valuation information for Excision is not publicly available.

Can I buy Excision stock?

Excision shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Excision's last funding round?

Excision's most recent funding round was Convertible Debt on February 17, 2021.

Who are the main investors in Excision?

Key investors in Excision include GreatPoint Ventures, GreatPoint Ventures, WRVI Capital, ARTIS Ventures.

Will Excision IPO soon?

No public IPO plans have been announced for Excision.

How can I track Excision secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Excision's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range11
Year Founded2015
Last FundingSep 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?